Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

Rhea-AI Summary

Zhongchao Inc. (NASDAQ: ZCMD) has launched the Hematology MDT Platform, an online training resource designed to enhance multidisciplinary treatment (MDT) skills for healthcare professionals. This platform facilitates real-time collaboration and problem-solving among physicians by providing access to expert guidance and training videos. As of August 2021, over 10,000 physicians have engaged with this platform, highlighting the growing demand for MDT in treating complex diseases like hematology within China. The company aims to expand this model across other medical areas to improve healthcare efficiency.

Positive

• Launch of Hematology MDT Platform to enhance multidisciplinary treatment skills.
• Over 10,000 physicians engaged on the platform as of August 2021, indicating significant interest.
• Potential to improve healthcare efficiency and quality in China.

Negative

• Risks associated with the implementation and acceptance of the MDT model in the market.

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform"). The Hematology MDT Platform provides clinicians with a channel to learn multidisciplinary thinking skills online, in order to improve diagnosis and treatment and further the efficiency of treatment. MDT is a medical service model in which multidisciplinary specialists discuss cases of a certain disease or a systemic disease and then develop an optimal treatment plan for the patient taking into considerations of opinions from all disciplines. Experienced physicians are essential and needed to organize and implement the MDT model as the model requires standardized multidisciplinary collaboration with high-level patient participation.

The Hematology MDT Platform is an online learning platform for front-line physicians, adopting Web real-time communication, or WebRTC technology where there are MDT theory module, practical exercise module, expert guidance module, and core issue interactive discussion module. Physicians can log in to Zhongchao's MDMOOC platform to submit cases and problems encountered during patient consultation and treatment and seek solutions from multidisciplinary experts in real-time. In addition, physicians can watch MDT training videos to learn the clinical thinking skills from experts and improve their problem-solving ability during the disease diagnosis and treatment.

The Hematology MDT Platform has gathered many authoritative experts in multiple disciplines related to hematology, including experts and front-line clinicians in hematology, infectious diseases, microbiology, immunology, blood transplantation from the Chinese Medical Association, Chinese Medical Doctor Association, ECCMID, Peking University People's Hospital, The First Affiliate Hospital of GUANGZHOU Medical University, 301 Hospital, Fudan University Zhongshan Hospital, Shanghai Tongji Hospital, Ruijin Hospital, Army Medical University Affiliated Hospital, Chongqing Medical University No.1 Affiliated Hospital, Hainan General Hospital, Shenzhen People's Hospital, The First Affiliated Hospital of College of Medicine Zhejiang University and The Second Affiliated Hospital of College of Medicine Zhejiang University. As of August 2021, more than 10,000 physicians have logged into the Hematology MDT Platform to participate in learning and discussion.

In the United States, MDT has been widely used to diagnose of and treat complex diseases such as cancer, cardiovascular diseases, and neurological diseases, with more than 90% of large hospitals using the MDT model. According to the list of the first batch of pilot hospitals for multidisciplinary diagnosis and treatment for tumor (digestive system) announced by the National Health Care Commission on November 30, 2018, there were 231 tertiary class A hospitals implementing MDT in China, accounting for 16% of tertiary class A hospitals and 9% of tertiary hospitals. As a result, the management of the Company believes that there is a huge demand for the application and popularization of MDT model in China. Zhongchao's Hematology MDT platform provides physicians with a convenient and rapid access to learn and exchange MDT practices and experiences and will promote the development of hematology treatment models in China. Looking forward, Zhongchao hopes to apply its MDT model to other treatment areas, promote the popularization and development of MDT in China, and improve medical treatment efficiency and quality.

About Zhongchao Inc.

Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is a platform-based internet technology company.  It provides online healthcare information, professional training and educational services to healthcare professionals under its "MDMOOC" platform (www.mdmooc.org) and to the public under its "Sunshine Health Forums" platform (www.ygjkclass.com) in China. Through its subsidiaries, the Company also operates a platform offering patient management services. More information about the Company can be found at its investor relations website at http://izcmd.com.  

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987

Investor Relations: Sherry Zheng  
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com  
Phone: +1 718-213-7386

View original content:https://www.prnewswire.com/news-releases/zhongchao-inc-launches-hematology-mdt-training-platform-to-improve-diagnosis-and-treatment-301379271.html

SOURCE Zhongchao Inc.

FAQ

What is the Hematology MDT Platform launched by Zhongchao Inc.?

The Hematology MDT Platform is an online training resource aimed at improving multidisciplinary thinking and treatment skills for healthcare professionals.

How many physicians have used the Hematology MDT Platform as of August 2021?

As of August 2021, over 10,000 physicians have logged into the Hematology MDT Platform.

What is the significance of the MDT model in healthcare?

The MDT model allows for collaboration among specialists to create optimal treatment plans for complex diseases, improving diagnosis and treatment efficiency.

What does Zhongchao Inc. aim to achieve with the Hematology MDT Platform?

Zhongchao aims to enhance the application of the MDT model in hematology and expand its use in other medical treatment areas.

When was the Hematology MDT Platform launched by Zhongchao Inc.?

The Hematology MDT Platform was announced on September 17, 2021.